drugset
drugset / Trial / NCT06692192

The RECAP2 Study: Midazolam and Psilocybin

NCT06692192 ↗

Phase 1 Recruiting 60 enrolled University of Wisconsin, Madison Vail Health Foundation · collab
RandomizedParallel-groupTriple-blindBasic science

Summary

The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing. Participants will: * Receive one of four possible combinations of medications * Undergo an MRI * Complete questionnaires * Undergo transcranial magnetic stimulation (TMS) and EEG

Timeline

Start
2025-08-07
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule — Intravenous
Subject Psilocybin Other / unclassified 1 mg —
Subject Psilocybin Other / unclassified 25 mg —

Indications

No indication recorded.